• KOL
    • KOLs Community
    • Prostate
    • Prostate Cancer
    • Hans Christiansen
    • Hans Christiansen

      Hans Christiansen

      Department of Radiation Oncology, Hanover Medical School, Hanover, Germany. | Clinic for Radiotherapy and Special Oncology of the Hannover Medical School, Hannover, Germany. | ...

       

       

      KOL Resume for Hans Christiansen

      Year
      2022

      Department of Radiation Oncology, Hanover Medical School, Hanover, Germany.

      Klinik für Strahlentherapie und Spezielle Onkologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

      2021

      Department of Radiotherapy, Hannover Medical School, Hannover, Germany.

      Comprehensive Cancer Center Niedersachsen (CCC-N), Hannover Medical School, Hannover, Germany

      Klinik für Strahlentherapie u. Spezielle Onkologie, Medizinische Hochschule Hannover/MHH, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

      2020

      Department of Radiotherapy and Special Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

      2019

      Department of Radiation Oncology, Hannover Medical School (MHH), Carl-Neuberg-Straße 1, 30625, Hannover, Germany

      2018

      Department of Radiation Oncology, Medical School Hannover, Hannover, Germany.

      Strahlentherapie und Spezielle Onkologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

      2017

      From the Departments of *Nuclear Medicine, †Medical Physics and Radiation Protection, ‡Urology and Urological Oncology, and §Radiation and Special Oncology, Hannover Medical School, Hannover; and ∥Department of Pharmaceutical Radiochemistry, Technical University Munich, Munich, Germany.

      Department of Radiotherapy, Medical School Hannover, Germany

      2016

      Clinics of Radiation Oncology, Hannover Medical School, Carl-Neuberg-Straße 1, D-30625 Hannover, Germany

      2015

      Department of Radiation Oncology, Medical School Hannover, Hannover, Germany

      Strahlentherapie und Spezielle Onkologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

      2014

      Department of Radiotherapy and Radiation Oncology, University Medical Centre, Georg-August-University Goettingen, Goettingen, Germany

      2013

      Department of Pediatric Hematology and Oncology, University Medical Center Leipzig, Leipzig, Germany

      Hannover Medical School Clinic of Radiation Oncology

      2012

      Department of Radiation Oncology, University of Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

      Klinik für Strahlentherapie und spezielle Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland

      2011

      Departments of aRadiotherapy and Radiooncology,

      Department of Radiotherapy and Radiation Oncology, University Clinic of the Georg August University, Robert-Koch-Str. 40, D-37099 Göttingen, Germany

      2010

      Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany

      2009

      From the Departments of Otorhinolaryngology-Head and Neck Surgery (Rödel, Matthias, Blomeyer), Radiotherapy and Radio-oncology (Wolff, Christiansen), and Medical Statistics (Jung), University of Göttingen, Göttingen, Germany.

      Department of Radiotherapy and Radiooncology, University Hospital Göttingen, Robert-Koch-Straße, Germany

      Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland

       

       

      Hans Christiansen: Influence Statistics

      Sample of concepts for which Hans Christiansen is among the top experts in the world.
      Concept World rank
      100 years hypofractionation #1
      update kombinierten #1
      beta nasopharyngeal #1
      hrt acute #1
      subject 100 years #1
      comorbidities nrct‑s #1
      definitive cure setting #1
      clinicspecific basis #1
      tlm case #1
      mac neoplasms humans #1
      radio publication humans #1
      ischemia rtpi #1
      experience hfsrt #1
      rapidarc conventional imrt #1
      nasopharyngeal neoplasms update #1
      radiotherapy psma #1
      beam liver #1
      radiotherapy 1993 #1
      elektive neckdissektion ersparen #1
      cancer tlm #1
      modernisierter klassiker #1
      subgroup analyses comorbidities #1
      overview single dose #1
      definitive hrt #1
      elektive neck #1
      groups definitive radiochemotherapy #1
      postoperative radiotherapy 112 #1
      palliative radiotherapy metastases #1
      kombinierten radio #1
      head carboplatin chemoradiotherapy #1
      specific kurzzeitantihormonbehandlung #1
      cci recurrence #1
      lower cci values #1
      neckdissektion female head #1
      median psa level #1
      patients biochemical progression #1
      radiochemotherapy drct #1
      primary laser resection #1
      toxicity grade #1
      oncological tlm #1
      oar rapidarc #1
      survival loco #1
      microsurgery carcinoma #1
      patienten hnokarzinomen #1
      incubation lncap #1
      nrct‑s cci values #1
      hnokarzinomen neckdissektion #1
      months nrct‑s #1
      normofractionated 3drt #1
      cci subgroup analyses #1

       

      Prominent publications by Hans Christiansen

      KOL-Index: 14827

      A quantitative imaging biomarker is desirable to provide a comprehensive measure of whole-body tumor burden in patients with metastatic prostate cancer, and to standardize the evaluation of treatment-related changes. Therefore, we evaluated whether prostate-specific membrane antigen (PSMA) ligand PET/CT may be applied to provide PSMA-derived volumetric parameters for quantification of whole-body tumor burden. Methods: One hundred one patients who underwent 68Ga-PSMA I&T PET/CT because of ...

      Known for Tumor Burden | Volumetric Parameters | Prostate Cancer | Psa Levels | Imaging Biomarker
      KOL-Index: 14552

      Purpose68Ga-labeled prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) has shown promising results in patients with biochemical recurrence after primary therapy for prostate cancer. In this study, we evaluated the usefulness of PSMA I&T (imaging and therapy) PET/CT prior to radical prostatectomy.MethodsThe study population consisted of 21 patients with prostate cancer who underwent 68Ga-PSMA I&T PET/CT before either open or ...

      Known for Radical Prostatectomy | Psma Pet | Prostate Cancer | Seminal Vesicle | Ece Svi
      KOL-Index: 14456

      Triple-negative breast cancer (TNBC) is an aggressive form of breast carcinoma with a poor prognosis. Recent evidence suggests that some patients with TNBC harbour germ-line mutations in DNA repair genes which may render their tumours susceptible to novel therapies such as treatment with PARP inhibitors. In the present study, we have investigated a hospital-based series of 40 German patients with TNBC for the presence of germ-line mutations in BRCA1, BRCA2, PALB2, and BRD7 genes. ...

      Known for Brca1 Brca2 | Negative Breast | Estrogen Receptors | Germline Mutations | Palb2 Mutation
      KOL-Index: 14252

      PurposeThe aim of this study was to assess the value of dual-time point imaging in PET/CT for detection of biochemically recurrent or persistent prostate cancer, using the prostate-specific membrane antigen (PSMA) ligand [68Ga]PSMA I&T.Methods240 patients who underwent a [68Ga]PSMA I&T PET/CT in the context of biochemical relapse of prostate cancer were included in this retrospective analysis. Imaging consisted of a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p.i.) ...

      Known for Biochemical Recurrence | Prostate Cancer | Delayed Imaging | Specific Antigen | Detection Rate
      KOL-Index: 12629

      PURPOSE: To prospectively analyze hepcidin, hemojuvelin, and ferroportin-1 expression after x-irradiation of rat liver and isolated rat hepatocytes.

      MATERIALS AND METHODS: The treatment of the rats and this study were approved by the local committee and the public authority on animal welfare. Rat livers in vivo and isolated rat hepatocytes in vitro were irradiated. The total number of rats in this study was 43. RNA extracted from livers (1, 3, 6, 12, 24, and 48 hours after irradiation) ...

      Known for Rat Liver | Gene Expression | Irradiated Hepatocytes | Radiation Induced | Hepcidin Hemojuvelin
      KOL-Index: 12510

      PURPOSE: To evaluate the efficacy of an adjuvant radiotherapy after transoral laser microsurgery for advanced squamous cell carcinoma of the head and neck and to show that a less invasive surgery with organ preservation in combination with radiotherapy is an alternative to a radical treatment.

      PATIENTS AND METHODS: Between 1987 and 2000, 208 patients with advanced squamous cell carcinoma of the head and neck were treated with postoperative radiotherapy after surgical CO2 laser resection. ...

      Known for Adjuvant Radiotherapy | Transoral Laser Microsurgery | Head Neck | Carcinoma Squamous | Neoplasms Laser
      KOL-Index: 12481

      PURPOSE: To determine the patterns of progression after 68Ga prostate-specific membrane antigen (PSMA)-ligand positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy (RT) for recurrent oligometastatic prostate cancer (PCa).

      METHODS AND MATERIALS: One hundred and eight patients with increased prostate-specific antigen levels, who received 68Ga-PSMA-ligand PET/CT-guided RT for recurrent oligometastatic disease after primary therapy for PCa were included. The ...

      Known for Recurrent Prostate Cancer | Ligand Pet | Patterns Progression | Radiation Therapy | Patients Biochemical
      KOL-Index: 12152

      OBJECTIVE: To report the oncologic and functional outcomes of transoral laser microsurgery (TLM) in the treatment of advanced laryngeal cancer.

      DESIGN: Prospective case series study.

      SETTING: Multi-institution (academic, tertiary referral centers).

      PATIENTS: A total of 117 patients with pathologically confirmed T2 to T4 lesions, stage III or stage IV, glottic or supraglottic carcinoma of the larynx were treated with TLM from 1997 to 2004. All patients had a minimum follow-up period of 2 ...

      Known for Advanced Laryngeal Cancer | Transoral Laser Microsurgery | Tlm Patients | Local Control | 2 Years
      KOL-Index: 11656

      OBJECTIVE: Acute radiation proctitis is a relevant complication of pelvic radiation. The purpose of this study was to investigate two markers of gut inflammation as non-invasive diagnostic tools to evaluate acute radiation proctitis.

      MATERIAL AND METHODS: Twenty patients who underwent radiotherapy for prostate cancer took part in this prospective study. Radiation-induced toxicity was evaluated weekly during radiotherapy in compliance with the CTC toxicity criteria. Stool samples from ...

      Known for Radiation Proctitis | Faecal Calprotectin | Prostate Cancer | Patients Radiotherapy | Lactoferrin Leukocyte
      KOL-Index: 11560

      PurposeTo assess the differences in the target volume (TV) delineation of metachronous lymph node metastases between 68 Ga-PSMA ligand PET/CT and conventional imaging in a comparative retrospective contouring study.Patients and methodsTwenty-five patients with biochemical prostate cancer recurrence after primary prostatectomy underwent 68 Ga-PSMA ligand PET/CT in addition to conventional imaging techniques such as CT and/or MR imaging for restaging. All patients were diagnosed with at ...

      Known for Prostate Cancer | Lymph Node | Conventional Imaging | Target Volume Delineation | Psma Ligand
      KOL-Index: 11382

      BACKGROUND: Approximately 40-70% of biochemically recurrent prostate cancer (PCa) is oligorecurrent after prostate-specific membrane antigen (PSMA) positron emission tomography (PET) staging. Metastasis-directed radiotherapy (MDT) of PSMA-positive oligorecurrence is now frequently used, but the role of concurrent androgen deprivation therapy (ADT) remains unclear.

      OBJECTIVE: To determine the effect of concurrent ADT with PSMA PET-directed MDT on biochemical progression-free survival ...

      Known for Androgen Deprivation | Prostate Cancer | Positron Emission | Directed Radiotherapy | Brfs Mdt
      KOL-Index: 10699

      ObjectiveUrinary radiotracer excretion of 68Ga-Labelled prostate-specific membrane antigen (PSMA) ligands may complicate the assessment of the prostate region and differentiation of lymph nodes from ureteral activity. The aim of this study was to assess the value of delayed imaging after forced diuresis.Materials and methodsSixty-six patients underwent 68Ga-PSMA I&T PET/CT for evaluation of prostate cancer at 60 min post-injection. In subgroups of patients, this was amended by delayed ...

      Known for Forced Diuresis | Delayed Imaging | Prostate Cancer | Image Quality | Tracer Injection
      KOL-Index: 10654

      Bloom’s syndrome is a rare autosomal recessive chromosomal instability disorder with a high incidence of various types of neoplasia, including breast cancer. Whether monoallelic BLM mutations predispose to breast cancer has been a long-standing question. A nonsense mutation, p.Q548X, has recently been associated with an increased risk for breast cancer in a Russian case–control study. In the present work, we have investigated the prevalence of this Slavic BLM founder mutation in a total ...

      Known for Breast Cancer | Nonsense Mutation | Bloom Syndrome | Blm Gene | Disease Heterozygote Humans
      KOL-Index: 10636

      PurposeThe goal of this work was to evaluate the early efficacy of 68Ga-PSMA ligand PET/CT imaging for radiotherapy of locally recurrent and/or oligometastatic prostate cancer.Patients and methodsA total of 29 patients with biochemical recurrence received a 68Ga-PSMA ligand PET/CT for restaging of disease, followed by 3D conformal radiotherapy of metastases or intensity-modulated radiation therapy of the prostate bed. Prostate-specific antigen (PSA) levels and imaging procedures served ...

      Known for Ligand Pet | Locally Recurrent | Radiotherapy Patients | Oligometastatic Prostate | Median Followup
      KOL-Index: 10527

      Purpose[68Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68Ga3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68Ge/68Ga-generator. We evaluated the clinical detection rates of [68Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy.MethodsConsecutive patients (n=99) referred for evaluation of biochemical relapse ...

      Known for Prostate Cancer | Pet Imaging | Detection Rates | Biochemical Recurrence | Primary Therapy

      Key People For Prostate Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Peter T Scardino
      prostate cancer active surveillance erectile function
      #3
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #4
      Johnathan I Jonathan
      prostate cancer gleason score needle biopsy
      #5
      Philip W Kantoff
      prostate cancer psma adc androgen deprivation therapy
      #6
      PATRICK CRAIG Walsh
      prostate cancer specific antigen pathological stage

      Hans Christiansen:Expert Impact

      Concepts for whichHans Christiansenhas direct influence:Prostate cancer,  Breast cancer,  Adjuvant radiotherapy,  Rectal cancer,  Acute toxicity,  Transoral laser microsurgery,  Kupffer cells,  Hepatocyte transplantation.

      Hans Christiansen:KOL impact

      Concepts related to the work of other authors for whichfor which Hans Christiansen has influence:Breast cancer,  Radiation therapy,  Psma pet,  Nasopharyngeal carcinoma,  Transoral laser microsurgery,  Squamous cell,  Biochemical recurrence.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Department of Radiation Oncology, Hanover Medical School, Hanover, Germany. | Clinic for Radiotherapy and Special Oncology of the Hannover Medical School, Hannover, Germany. | Klinik für Strahlentherapie und Spezielle Onkologie, Medizinische Hochschu

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.